Edition:
India

Vanda Pharmaceuticals Inc (VNDA.OQ)

VNDA.OQ on NASDAQ Stock Exchange Global Market

13.60USD
12 Dec 2017
Change (% chg)

$-0.25 (-1.81%)
Prev Close
$13.85
Open
$13.90
Day's High
$13.95
Day's Low
$13.35
Volume
132,386
Avg. Vol
151,814
52-wk High
$18.95
52-wk Low
$11.90

Select another date:

Sat, Nov 11 2017

BRIEF-Vanda receives negative opinion for marketing authorization from the European Medicines Agency

* Vanda receives negative opinion for marketing authorization from the European Medicines Agency on fanaptum™ for the treatment of schizophrenia

BRIEF-Vanda Pharmaceuticals posts qtrly ‍net loss of $0.10​/share

* Qtrly ‍net loss per share $0.10​ Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

BRIEF-Vanda Pharmaceuticals reached a pricing agreement with the German National Association of Statutory Health Insurance Funds

* Vanda Pharmaceuticals - On Oct 17, co reached a pricing agreement with the German National Association of Statutory Health Insurance Funds

BRIEF-Vanda Pharmaceutical ‍announced results from study of Tradipitant as a treatment of chronic pruritus

* Vanda Pharmaceuticals Inc - ‍announced results from randomized phase ii clinical study of Tradipitant as a monotherapy in treatment of chronic pruritus

BRIEF-Vanda Pharmaceuticals qtrly ‍net loss per share $0.03​

* Vanda Pharmaceuticals Inc - ‍total net product sales were $42.1 million in Q2 of 2017​

BRIEF-Vanda receives negative opinion for marketing authorization from the EMA on Fanaptum

* Vanda receives negative opinion for marketing authorization from the European Medicines Agency on Fanaptum™ for the treatment of schizophrenia

BRIEF-Armistice Capital Llc reports 5.1 pct passive stake in Vanda Pharmaceuticals Inc

* Armistice Capital Llc reports a 5.1 percent passive stake in Vanda Pharmaceuticals Inc as of June 7 - sec filing Source text for Eikon: (http://bit.ly/2rwELbT) Further company coverage:

Select another date: